Logo

About Us

Regor Therapeutics Group is a clinical-stage biotechnology company developing innovative and clinically differentiated medicines, with an in-house pipeline encompassing leading assets in oncology, metabolism and auto-immunity. By leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, Regor Therapeutics Group has completed 10+ PCCs inhouse, with 3 assets with clinical data, validating its highly efficient ecosystem for accelerated discovery of innovative therapeutic agents.

Our Pipeline

Regor has a portfolio of differentiated drug candidates focused on therapeutic areas with huge unmet needs: metabolism, oncology and auto-immunity.

Clinical pipeline of potential blockbusters:
1) RGT-075, a leading once-daily oral small molecule full agonist of GLP-1R;
2) RGT-419B, the only CDK4 inhibitor with single agent efficacy in refractory ER+/HER2- breast cancer.


Press Releases

  • 5 June, 2024

    Regor to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

    +Read More+

  • 8 March, 2024

    Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity

    +Read More+

  • 7 December, 2023

    Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy

    +Read More+

  • 27 November, 2023

    Regor Announces Poster Presentations of RGT-419B, A Next Generation CDK4 Inhibitor at the San Antonio Breast Cancer Symposium (SABCS)

    +Read More+

  • 03 November, 2022

    Regor announces China NMPA approval of the IND for RGT-264 phosphate tablet, a potent and selective HPK1 inhibitor

    +Read More+

  • 20 April, 2022

    Regor announces China NMPA approval of the IND for RGT-419B capsule, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer

    +Read More+

  • 8 April, 2022

    Regor announces the first patient dosed in the U.S. in the Phase I clinical trial for RGT-419B, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer

    +Read More+

  • 10 Dec, 2021

    Regor and Lilly Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders

    +Read More+

  • 18 Feb, 2021

    Regor Therapeutics Announces Completion of $90 Million Series B Financing

    +Read More+
245 Main Street, Second Floor, Cambridge, MA 02142, USA